Reported 1 day ago
Viking Therapeutics, Inc. (VKTX), valued at $3 billion, is increasingly viewed as an undervalued stock, especially with its oral weight loss drug VK2735 demonstrating promising results in phase 2 trials, achieving rapid weight loss similar to competitors in much shorter timeframes. With a significant short interest and potential for a buyout as the GLP-1 market grows, analysts suggest VKTX could achieve substantial price increases, with projections exceeding $120 compared to its current trading price in the mid-$20s. This bullish outlook emphasizes the company's unique position and potential for high returns amid growing retail interest.
Source: YAHOO